Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma

NCT02340156 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Conditions

RECURRENT GLIOBLASTOMA

Interventions

GENETIC: SGT-53
DRUG: Temozolomide

Sponsor

SynerGene Therapeutics, Inc.